This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D86.1 (Sarcoidosis of lymph nodes) | Special Copayment Reduction: V111 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Lymph node sarcoidosis, lymph node granulomatosis, Sarcoidosis of lymph nodes, mediastinal lymph node sarcoidosis, hilar lymph node sarcoidosis, peripheral lymph node sarcoidosis |
| C. Adult onset | Very likely to first manifest in adulthood — most commonly manifests in adults aged 25–50; isolated lymph node sarcoidosis, with lymphadenopathy as the main finding, is often found incidentally at health checkups as hilar or mediastinal lymphadenopathy. Childhood onset is rare. |
| 1. History | 1877 Hutchinson describes sarcoid including lymphadenopathy → 1934 Schaumann establishes the concept of systemic lymph node granulomas → 1958 Scadding classifies stage 1 (bilateral hilar lymphadenopathy) → introduction of EBUS in the 1990s revolutionizes mediastinal lymph node biopsy → use of PET-CT in the 2000s. |
| 2. Causes | Same polygenic cause as pulmonary sarcoidosis. Genetic predisposition (HLA-DRB1, etc.) + environmental antigens (microbes, organic and inorganic dust) → non-caseating granuloma formation within lymph nodes. The main route is antigen inhalation followed by accumulation in lymph nodes via the lymphatic vessels. |
| 3. Genetics | Polygenic inheritance. Associated with HLA-DRB1, ANXA11, and BTNL2 variants. Genetic factors determining the lymph node-specific phenotype have not been established. Familial aggregation (3–5 times higher risk in first-degree relatives). Not a single-gene disease. |
| 4. General epidemiology | Hilar and mediastinal lymph node involvement in ~90% of all sarcoidosis patients. Extrapulmonary lymph node involvement 15.3% (Korea). Chest X-ray stage 1 (lymphadenopathy alone) accounts for 36.8% of Korean patients. Isolated extrapulmonary lymph node involvement is rare. |
| 5. Pathophysiology | Antigen inhalation → antigen presentation by alveolar APCs → CD4+ Th1 activation → secretion of TNF-α and IFN-γ → macrophage differentiation into epithelioid cells → granuloma formation within lymph nodes. Normal lymph node tissue is replaced by granulomas while lymph node architecture is preserved. Route of systemic spread via lymph nodes. |
| 6. Symptoms | Thoracic lymph nodes: often asymptomatic (found on chest X-ray). Cough and chest discomfort due to hilar lymphadenopathy. Peripheral lymph nodes (cervical, axillary, inguinal): painless lymphadenopathy. Systemic symptoms: fever, fatigue, weight loss. Löfgren syndrome: bilateral hilar lymphadenopathy + erythema nodosum + arthralgia. |
| 7. Signs | Chest X-ray and CT: bilateral symmetric hilar and paratracheal lymphadenopathy (potato-shaped). PET-CT: high FDG uptake (SUV>2.5). Peripheral lymph nodes: painless, firm, mobile lymph nodes. Histology: non-caseating epithelioid granuloma. Elevated serum ACE and sIL-2R. |
| 8. Screening | Chest X-ray (detects hilar lymphadenopathy). Chest CT (evaluates lymph node size, distribution, and character). Measurement of serum ACE, calcium, and liver function. LDH, β2-microglobulin (to differentiate lymphoma). Superficial lymph nodes: ultrasound after palpation on physical examination. |
| 9. Diagnosis | EBUS-TBNA: biopsy of mediastinal and hilar lymph nodes (first-line recommendation, diagnostic yield 80–90%). Excisional biopsy of superficial lymph nodes. Tissue: non-caseating granuloma + exclusion of tuberculosis and fungi. PET-CT: selection of biopsy target sites. Differentiation from lymphoma (immunohistochemical staining). |
| 10. Treatment | Isolated lymph node involvement that is asymptomatic with normal lung function: observation. When symptomatic or progressive: oral steroids (prednisolone). Refractory or relapsing: methotrexate, infliximab. Treatment goals: symptom relief, prevention of progression to important organs such as the lung and heart. |
| 11. Prognosis | Isolated lymph node involvement (Scadding stage 1): spontaneous remission rate ~80%, good prognosis. Low proportion progressing from stage 1 to stage 2 or 3. Prognosis especially good for Löfgren syndrome (80–90% remission). Management of generalized fatigue and reduced quality of life is needed. |
| 12. Prevention | Minimize occupational dust exposure, smoking cessation. Detect progression early with regular chest X-ray, CT, and pulmonary function tests. Maintain differentiation from malignancies such as lymphoma. Prevent infectious complications during immunosuppressive treatment (vaccination, etc.). |
| 13. References | Gupta D et al. EBUS-TBNA in the diagnosis of sarcoidosis … and 9 other papers |
Lymph node sarcoidosis goes hand in hand with the very history of the formation of the disease concept of sarcoidosis. Since Jonathan Hutchinson reported in 1877 a case with peripheral lymph node enlargement together with skin lesions, lymph node involvement has been recognized as one of the key findings of sarcoidosis. Subsequently, Caesar Boeck's description of cutaneous granulomas in 1899, and Jörgen Schaumann's concept of Lymphogranulomatosis benigna (benign lymphogranulomatosis) in 1917, made a decisive contribution to establishing sarcoidosis as a systemic granulomatous disease that extensively involves lymph nodes and organs throughout the body. Schaumann emphasized that, unlike tuberculosis, this disease involves multiple organs, including lymph nodes, without caseous necrosis and has a relatively good prognosis.
Hilar lymphadenopathy came to be recognized as a characteristic and common radiographic finding in sarcoidosis with the spread of chest radiography. In 1958, John Scadding, in proposing the chest X-ray radiographic staging system, defined stage 1 as "bilateral hilar lymphadenopathy alone," and this stage 1 is still recognized as the stage with the best prognosis in sarcoidosis. In the 1970s–80s, the introduction of computed tomography (CT) made it possible to evaluate the size, distribution, and calcification of mediastinal lymph nodes more precisely.
A historical turning point in diagnostic methods came with advances in bronchoscopy technology after the 1990s. Transbronchial needle aspiration (TBNA) under bronchoscopy was introduced, and later, in the 2000s, EBUS-TBNA, combined with endobronchial ultrasound (EBUS), became widespread, making it possible to obtain tissue from mediastinal and hilar lymph nodes safely and with a high diagnostic yield without thoracic surgical intervention. The introduction of EBUS-TBNA changed the standard of diagnosis for lymph node sarcoidosis and greatly reduced the cases requiring surgical thoracoscopy or mediastinoscopy. Since the 2010s, PET-CT (positron emission tomography) has been used for whole-body evaluation of active lymph node involvement and selection of biopsy target sites.
In Korea, as awareness of sarcoidosis increased after the 2000s, cohort studies on the characteristics of lymph node involvement were published. In a Korean patient cohort (2021, Scientific Reports), extrapulmonary lymph node involvement was observed in 15.3% of the total, following skin (24.3%) and eyes (19.9%), the most common sites of extrapulmonary involvement. Clinically, chest X-ray stage 1 (hilar lymphadenopathy alone) accounted for about 36.8% of Korean patients, confirming that the form with the best prognosis is the most common.
Lymph node sarcoidosis is an organ-specific expression of the same systemic granulomatous disease as pulmonary sarcoidosis, so its causes are also shared. According to current understanding, an abnormal T-cell-mediated immune response to specific environmental antigens in genetically susceptible individuals leads to the formation of non-caseating granulomas within lymph nodes. It is a multifactorial disease in which genetic, environmental, and immunologic factors are involved in combination rather than a single cause.
Environmental antigens being studied as main candidates include Mycobacterium tuberculosis-derived antigens (KatG, ESAT-6, etc.), Cutibacterium acnes antigens, organic dust (organic dust, mold spores, pollen), and inorganic substances (silica, beryllium, aluminum). When these antigens reach the lungs by inhalation, they are phagocytosed by alveolar dendritic cells and macrophages and migrate through nearby lymphatic vessels to the hilar and mediastinal lymph nodes, where antigen presentation takes place. In this process, in genetically susceptible individuals an excessive Th1 cell response persists and granulomas form within the lymph nodes. This explains why lymph nodes, particularly hilar and mediastinal lymph nodes, are the most commonly involved in sarcoidosis.
In peripheral lymph node involvement, antigen exposure through percutaneous or mucosal routes may be involved. Peripheral lymph nodes such as cervical, axillary, and inguinal nodes process antigens entering from the skin or mucosa, so they often occur simultaneously with cutaneous sarcoidosis. Occupational exposure (firefighters, mining, agriculture, metalworking) and granulomatous reactions caused by some drugs or biologics (so-called "drug-induced sarcoid reaction") should also be considered as causes. In particular, immune activation by cancer immunotherapy agents (immune checkpoint inhibitors, anticancer monoclonal antibodies) can induce a sarcoid-like granulomatous lymph node reaction, and differentiation from malignancy is clinically important.
The distribution of lymph node involvement is clinically meaningful. Symmetric bilateral hilar lymphadenopathy is highly characteristic of sarcoidosis, whereas unilateral or asymmetric lymphadenopathy more strongly suggests other diseases such as lymphoma, metastatic cancer, and tuberculosis. Abdominal lymph node sarcoidosis also occurs rarely and can cause portal hypertension and gastrointestinal symptoms. In this way, the pattern and distribution of involvement in lymph node sarcoidosis provide key information for diagnosis and differential diagnosis.
Sarcoidosis overall, including lymph node sarcoidosis, is a polygenic disease; there is no single causative gene, and multiple gene variants and environmental factors act in combination. Familial aggregation is observed, and the risk of disease in first-degree relatives of sarcoidosis patients is 3–5 times higher than in the general population. The concordance rate in monozygotic twins is about 40%, and both genetic and environmental factors contribute to onset.
The gene most consistently associated with sarcoidosis is HLA-DRB1. HLA-DRB1 encodes the MHC II molecule that presents antigenic peptides to CD4+ T cells, and the spectrum of presented antigens varies with the specific allele, determining the nature of the immune response. HLA-DRB1*0301 and *0101 are associated with Löfgren syndrome (acute presentation, including bilateral hilar lymphadenopathy) and show a good prognosis, whereas DRB1*1501 is associated with chronic progressive sarcoidosis, particularly pulmonary fibrosis. An HLA allele association that specifically determines the lymph node involvement phenotype has not yet been clearly established.
Associated genes other than HLA include mainly ANXA11 (annexin A11) and BTNL2. The ANXA11 R230C variant has been repeatedly reported to be associated with increased sarcoidosis risk in multiple ethnic groups. ANXA11 is involved in cell division, apoptosis, and RNA granule regulation, and it has been proposed that this variant may affect immune cell survival and activation. BTNL2 (butyrophilin-like 2) is a negative regulator of T-cell activation, and it is presumed that with BTNL2 variants the T-cell activation-inhibiting function is reduced, so an excessive granuloma-forming response can easily occur. In addition, TNF-α promoter variants, NOD1/NOD2 variants, and IL-12 pathway gene variants have been reported in some studies, but reproducibility is insufficient.
There is evidence that genetic background affects the extent of lymph node involvement and prognosis. Löfgren syndrome is strongly associated with the HLA-DRB1*0301 allele, and bilateral hilar lymphadenopathy, the characteristic finding of this syndrome, shows a very good spontaneous remission prognosis. In contrast, in individuals with HLA-DRB1*1501, hilar lymphadenopathy persists and the likelihood of progression to pulmonary fibrosis is high. Genetic testing is not currently included among standard diagnostic tools, but its potential use for personalized prognosis prediction and treatment selection in the future is being studied.
Lymph node involvement is very common in sarcoidosis. Thoracic lymph node (hilar and mediastinal) involvement occurs in about 90% or more of all sarcoidosis patients and is most commonly confirmed as bilateral symmetric hilar lymphadenopathy on chest X-ray or CT. By the Scadding staging system, stage 1 (hilar lymphadenopathy alone) accounts for a substantial proportion of all patients: 36.8% in a Korean patient cohort study and about 30–50% in Western patients.
Extrapulmonary lymph node involvement (cervical, axillary, inguinal, mesenteric lymph nodes, etc.) occurs in about 15–30% of all sarcoidosis patients. It was reported as 15.3% in a Korean cohort study, and the main sites of involvement are cervical, axillary, and inguinal nodes. Isolated extrapulmonary lymph node involvement (only peripheral lymph nodes involved without thoracic involvement) is relatively rare, accounting for less than 5% of all sarcoidosis, and in this case differentiation from lymphoma and other causes is clinically very important. Intra-abdominal lymph node (mesenteric, retroperitoneal, porta hepatis, etc.) sarcoidosis is even rarer, estimated at about 1–5% of all sarcoidosis.
In the overall epidemiologic data for sarcoidosis, age at onset is concentrated in the 20s–50s, and in Korea the proportion of cases in the 50s–60s is also increasing. The sex distribution shows a slightly higher morbidity rate in women. Worldwide prevalence is 10–20/100,000, and in Korea it was reported as 9.37/100,000 (National Health Insurance data, 2003–2015). Lymph node sarcoidosis (D86.1) is diagnosed independently far less often than pulmonary sarcoidosis (D86.0), and most cases are accompanied by lung involvement (classified as D86.2).
Mortality in lymph node sarcoidosis is low, and the spontaneous remission rate reaches about 80% in stage 1 (hilar lymphadenopathy alone) patients. However, some lymph node sarcoidosis also follows a chronic course or may progress to important organs such as the lung and heart, so regular follow-up is important. An association with metabolic diseases accompanying sarcoidosis (diabetes, hypertension) has also been reported in recent domestic studies, so multifaceted health management is needed.
The pathophysiology of lymph node sarcoidosis shares the mechanism of systemic sarcoidosis and is understood centering on the process of granuloma formation within the lymph node, a specialized immune organ. Environmental antigens inhaled or penetrating through the lungs or another route are phagocytosed by dendritic cells (DC) and macrophages. These antigen-presenting cells (APC) migrate through lymphatic vessels to the hilar and mediastinal lymph nodes and present antigen to CD4+ T cells within the lymph nodes.
After antigen presentation, CD4+ T cells differentiate mainly toward Th1 and secrete IL-2, IFN-γ, TNF-α, and others. These cytokines further activate macrophages within lymph nodes, causing them to differentiate into epithelioid cells and form multinucleated giant cells (Langhans-type giant cells). Activated macrophages, epithelioid cells, surrounding lymphocytes, and fibroblasts become organized to form non-caseating, non-necrotizing granulomas within the lymph node. Initially the overall architecture of the lymph node (cortex, paracortex, medulla, lymphatic sinuses) is preserved to some extent, but as the number and size of granulomas increase, normal lymph node architecture is gradually replaced by granulomas.
TNF-α plays a very important role in granuloma formation within lymph nodes. TNF-α is a cytokine essential for maintaining the stability and formation of granulomas, which is also why anti-TNF-α biologics (infliximab, etc.) that block it are effective in treating refractory sarcoidosis. In addition, activated macrophages express 1α-hydroxylase and promote vitamin D activation, so hypercalcemia can occur in lymph node sarcoidosis as well. Concentration of CD4+ T cells within granulomas and a decrease in peripheral blood CD4+ T cells (lymphopenia) may occur, which acts as a factor slightly increasing the risk of tuberculosis co-infection in sarcoidosis.
The natural course of lymph node sarcoidosis is divided into two. In many cases granulomas resolve spontaneously or heal leaving traces of inactive fibrosis (spontaneous remission), and in this case lymph node size also decreases. However, in some patients granulomas persist and fibrosis progresses, so the lymph nodes continue to enlarge or compress surrounding structures. Fibrosis and calcification of hilar lymph nodes are chronic changes that can be observed on CT in long-standing sarcoidosis.
Lymph node sarcoidosis, particularly when thoracic (hilar and mediastinal) lymph node involvement is predominant, is in many cases found incidentally as asymptomatic on a health checkup chest X-ray or a CT taken for another purpose. This corresponds to Scadding stage 1, in which bilateral symmetric hilar lymphadenopathy is confirmed without symptoms. Some patients complain of mild dry cough, chest discomfort, and mild dyspnea, but these mostly arise from the effect of compression of surrounding bronchi by hilar lymphadenopathy without lung parenchymal involvement.
Systemic symptoms may include fatigue, malaise, fever, night sweats, and weight loss. These are reported in about 30–50% of patients with lymph node sarcoidosis. The acute form, Löfgren syndrome, is characterized by the triad of bilateral hilar lymphadenopathy, erythema nodosum (painful red nodules on the front of the lower legs), and arthralgia or arthritis (especially around the ankles), and presents abruptly with fever. It is common mainly in young women and in people of Northern European descent, and the spontaneous remission rate is very high (80–90%), so the prognosis is good. Recognizing this characteristic syndrome allows a clinical diagnosis in some cases without invasive biopsy.
Peripheral lymph node (cervical, axillary, inguinal) involvement presents as painless, mobile lymphadenopathy. The lymph nodes are firm but, unlike tuberculous lymphadenitis, there is no pus (abscess) or fistula formation. Cervical lymphadenopathy may appear together with parotid gland sarcoidosis, and this, when accompanied by fever and uveitis, is called Heerfordt syndrome (uveoparotid fever). Intra-abdominal lymph node involvement can cause abdominal discomfort, abdominal distension, and, rarely, symptoms of portal hypertension (ascites, splenomegaly).
On chest imaging, bilateral symmetric hilar lymphadenopathy is the most characteristic imaging finding of lymph node sarcoidosis. On chest X-ray, widening of the hila on both sides with rounded protrusions is observed ("potato-shaped" hila = potato sign). On CT, enlargement of the hilar and paratracheal lymph nodes (peribronchial and subcarinal lymph nodes) appears symmetrically, and the lymph nodes are homogeneous and enhance uniformly with contrast. Rarely, eggshell or punctate calcification is observed in long-standing lesions. Unilateral or highly asymmetric lymphadenopathy requires differentiation from lymphoma, tuberculosis, and metastatic cancer.
On PET-CT, active sarcoidosis lymph nodes show high FDG (fluorine-18 deoxyglucose) uptake, with an SUV (standardized uptake value) increased to 2.5 or more. This can also occur in lymphoma, so care is needed in differentiation, but PET-CT is useful for identifying sites of whole-body involvement and selecting the best site for biopsy. Peripheral lymph nodes are firm, mobile, and painless on palpation. On ultrasound, homogeneous hypoechoic lymph nodes are observed, and increased internal blood flow may be seen on Doppler.
On blood tests, serum ACE (angiotensin-converting enzyme) and soluble IL-2 receptor (sIL-2R) are used as markers of active sarcoidosis. ACE is secreted by macrophages within active granulomas and is elevated in active lymph node sarcoidosis (sensitivity 60–70%, specificity 75–85%). sIL-2R is secreted by activated T cells and has higher sensitivity than sACE. Serum calcium may also be elevated in lymph node sarcoidosis. LDH and β2-microglobulin help differentiate lymphoma. Histologically, non-caseating epithelioid granuloma is confirmed on lymph node biopsy, and tuberculosis is excluded by negative acid-fast bacilli staining and culture.
Initial screening for lymph node sarcoidosis is performed mainly with chest X-ray. The most common diagnostic pathway is the finding of bilateral hilar lymphadenopathy on a chest X-ray taken at a health checkup or for another reason. When an abnormality is suspected on chest X-ray, chest CT is performed to evaluate more accurately the size and distribution of the lymph nodes, calcification, and lung parenchymal involvement. When peripheral lymphadenopathy is present, ultrasound is used to check lymph node size, internal character, and blood flow.
For blood tests, along with serum ACE, a complete blood count (CBC), liver function tests, kidney function tests, serum calcium, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) are performed. LDH and β2-microglobulin are added to differentiate lymphoma. An interferon-gamma release assay (IGRA, QuantiFERON-TB Gold) is performed to exclude tuberculosis. Ophthalmologic examination (slit-lamp examination) is important for screening for eye involvement such as uveitis and is recommended once a year in all sarcoidosis patients. Pulmonary function tests (spirometry, DLco) are essential for assessing lung parenchymal involvement and the degree of functional impairment.
In the differential diagnosis of lymphadenopathy, the most important entity is lymphoma (Hodgkin and non-Hodgkin lymphoma). In lymphoma, unilateral or asymmetric lymphadenopathy, rapid growth, night sweats, weight loss, and elevated LDH are characteristic. Lymph node sarcoidosis is generally bilateral and symmetric, accompanied by elevated ACE, and concurrent involvement of the lung and other organs is observed on PET-CT. However, the two diseases can occur together (sarcoid-lymphoma syndrome), so tissue biopsy must be performed in suspicious cases.
Lymph node sarcoidosis is confirmed by identifying non-caseating epithelioid granuloma on tissue biopsy and excluding similar diseases such as tuberculosis and fungal infection. The diagnostic approach differs according to the location of the lymph nodes.
The standard method for thoracic (hilar and mediastinal) lymph node biopsy is endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). EBUS-TBNA uses an ultrasound probe attached to a bronchoscope to insert a needle through the bronchial wall into an adjacent lymph node and obtain cells or tissue. It can be performed without thoracic surgery, and diagnostic accuracy reaches 80–90%. The obtained specimen undergoes cytologic examination (Diff-Quik, etc.) together with cell block section examination, and tuberculosis is excluded by acid-fast bacilli staining (Ziehl-Neelsen) and culture. Performing bronchoscopic mucosal biopsy and TBLB (transbronchial lung biopsy) together also improves the diagnostic yield.
For peripheral lymph nodes, ultrasound-guided fine-needle aspiration (US-FNA) or excisional biopsy is performed. Excisional biopsy provides richer tissue information than fine-needle aspiration and is more advantageous for excluding lymphoma. Intra-abdominal lymph nodes are approached by CT- or ultrasound-guided percutaneous needle biopsy (CT-guided percutaneous biopsy). PET-CT identifies sites of whole-body involvement and metabolic activity and helps select the biopsy target site that is easiest to access and has the highest positive yield. Immunohistochemical staining (CD20, CD3, Ki-67, BCL-2, etc.) is used to differentiate lymphoma. A bronchoalveolar lavage (BAL) CD4/CD8 ratio >3.5 is a finding that strongly supports sarcoidosis and is used for adjunctive diagnosis.
The treatment principles for lymph node sarcoidosis are the same as for pulmonary sarcoidosis, and not all patients need treatment. For asymptomatic isolated thoracic lymph node involvement (Scadding stage 1) or mild symptoms, regular follow-up observation at 3–6 month intervals is performed first without immediate drug treatment, because the spontaneous remission rate is high. Treatment is started if symptoms worsen, radiologic findings progress, or lung function declines during the course.
When treatment is needed, the first-line drug is oral corticosteroids. Starting with prednisolone 0.5 mg/kg/day (generally 20–40 mg per day), symptoms, radiologic findings, and serum ACE are followed up after 4–6 weeks and the dose is gradually tapered. The treatment duration is generally 1–2 years. Steroids are also effective when there are symptoms due to lymph node compression (such as cough due to bronchial compression). Steroids are particularly effective when hypercalcemia is present, and a low-calcium diet and hydration are combined.
When refractory to steroids or when tapering is needed because of side effects, methotrexate (MTX, 10–15 mg once weekly, oral or subcutaneous) or azathioprine (2 mg/kg per day) is added as a second-line agent. These have a steroid-sparing effect and help reduce steroid side effects. For refractory lymph node sarcoidosis, infliximab (anti-TNF-α monoclonal antibody) may be used, and a higher remission rate than with steroids alone was confirmed in randomized controlled trials. In patients at risk of tuberculosis, exclusion of latent tuberculosis is essential before using infliximab.
The prognosis of lymph node sarcoidosis is relatively favorable among all sarcoidosis phenotypes. In particular, isolated thoracic lymph node involvement (Scadding stage 1) has a spontaneous remission rate of about 80%, and most cases remit even without treatment. Presentation as Löfgren syndrome (bilateral hilar lymphadenopathy + erythema nodosum + arthralgia) has the highest spontaneous remission rate at 80–90% and a low likelihood of chronicity. If symptoms persist for 2 years or more, the likelihood of a chronic course rises.
In the long term, the proportion progressing from stage 1 to stage 2 or 3 is relatively low (about 5–15%), but progression may be missed if follow-up is insufficient. In some patients, involvement of other organs, such as fatigue, neurosarcoidosis, and cardiac arrhythmia, may appear late even after lymph node sarcoidosis has remitted, so long-term follow-up is necessary. Direct death from lymph node sarcoidosis is rare, but if it progresses, pulmonary fibrosis, pulmonary hypertension, and cardiac involvement raise the risk of death. Nonspecific symptoms such as fatigue, sleep disturbance, and depression and anxiety are major factors reducing quality of life, and active management of these is needed.
No primary prevention for sarcoidosis has been established, but environmental management that minimizes exposure to the known risk factors of occupational dust, organic dust, and metal dust is recommended. In high-risk occupational groups such as firefighters, agricultural workers, and mining workers, wearing appropriate respiratory protection and improving ventilation of the work environment are important. Smoking cessation benefits overall lung health and is strongly recommended after the onset of sarcoidosis to prevent worsening of lung damage.
For secondary prevention after diagnosis, regular follow-up tests are key. Patients with lymph node sarcoidosis should have a chest X-ray, pulmonary function tests, serum ACE and calcium levels, and an ophthalmologic examination at 3–6 month intervals. During steroid treatment, prevention of osteoporosis (calcium and vitamin D supplementation) and monitoring of blood glucose and blood pressure are needed. A latent tuberculosis test (IGRA) is performed before treatment, and if needed, immunosuppressants are started after preventive anti-tuberculosis treatment. Influenza and pneumococcal vaccination are given to reduce the risk of infectious complications. During long-term follow-up, keep in mind the possibility of malignancy such as lymphoma, and re-evaluate immediately if suspicious findings occur.
Psychosocial support is also part of prevention. In sarcoidosis with a chronic course, fatigue, uncertainty, and occupational limitations can cause depression and anxiety, and recognizing these early and managing them appropriately is important for improving quality of life. Providing guidance on financial support through the domestic rare disease support system (Special Copayment Reduction V111, medical expense support program) and connection to patient support groups is also an important role of the clinician.